# Peripheral intravenous cannula

## Don't put them in. Get them out. Look after them properly.



Carolyn Kirker, RN BN, PG Cert healthcare CNS Infusion Therapy and Vascular Access, CCDHB



# Don't put them in



 In 2017 CCDHB managed 12 healthcare associated (HA) PIVC staph aureus bacteraemia (SAB). 1/3 of our / 36 medical device associated HA SAB.



# **Getting to the point**


- Multi-disciplinary clinical leadership partnership
  - Vascular Access and Treatment, Infection Prevention and Control, Clinical Practice committees
- Stewardship programmes Antimicrobial, Transfusion, TPN
- Vascular access as clinically indicated only
- Right device selection *adult and paediatric algorithms*
- Insertion or replacement as necessary not routinely
- Review of SOP *PRICT, amiodarone, scanning*
- Manage DIVAs hospital wide vascular access services
  - ultrasound or near infra red technologies for insertion to reduce attempts and facilitate compliance with standards
- Standardised management of indwelling devices
- ERAS and early discontinuation of IV fluids





### Get them out

- consensus on clinical indications for PIVC and measure compliance
- review clinical indications each shift:
  - is your patient drinking adequately?
  - have the IV medications been switched to oral?
  - is your patient safe without IV access?
- **only** resite peripheral intravenous cannula (PIVC) when clinically indicated
- ensure prompt removal at the completion of treatment or when the cannula is not needed.





### Practice Responsible Intravenous Cannulation Today! (PRICT) Project

 the median ED idle peripheral IV cannula (PIVC) prevalence value was 32.4% (1)

### **PRICT** guidelines:

- 3 questions before performing cannulation:
- Is my patient unstable or could they become seriously unstable?
- Is my patient highly likely to need IV fluids, medications or contrast?
- Does my patient have a specific condition that mandates an IV cannula?

- 31% average cannula insertion REDUCTION
- Venepuncture increased by 17%





# **Care bundles: insertion**

### Key elements

- hand hygiene
- ANTT key part/site protection
- appropriate skin antisepsis
- device selection size, design
- location
- documentation

#### **PERIPHERAL INTRAVENOUS CANNULA - INSERTION CARE BUNDLE**

Hand hygiene	<ul> <li>compliance with the 5 moments of hand hygiene</li> <li>hands decontaminated before clean glove application</li> </ul>
Personal protective equipment	<ul><li> clean gloves applied immediately prior to insertion</li><li> plastic apron applied if indicated</li></ul>
Skin preparation	<ul> <li>2% chlorhexidine gluconate in 70% isopropyl alcohol is applied and allowed to dry</li> <li>if patient sensitivity, use 10% povidone-iodine</li> <li>if indicated, hair is removed using clippers (not shaven) to improve dressing adherence</li> </ul>
Aseptic technique	<ul> <li>compliance with aseptic non-touch technique</li> <li>a new sterile cannula for all cannulation attempts</li> <li>a single use latex free tourniquet</li> </ul>
Dressing	<ul> <li>a sterile, semi-permeable, transparent dressing is applied allowing observation of insertion site</li> </ul>
Practice	<ul> <li>no more than two attempts at insertion by the same health care professional when alternative clinical support is available</li> <li>fluid administration containers, tubing and connectors must be replaced when a new PIVC is inserted</li> </ul>
Documentation	<ul> <li>date, catheter size, reason for insertion, location and operator undertaking insertion</li> <li>number of attempts if more than one and any associated complications</li> </ul>
Safety	<ul> <li>where available and not clinically contraindicated use safety equipped cannulation equipment</li> <li>sharps container for point of care disposal.</li> </ul>



# **Care bundles: maintenance**

### key elements:

- hand hygiene
- bung antisepsis
- aseptic non-touch technique key part/site protection
- location, securement and immobilisation
- dwell frequencies and interactions
- documentation
- tubing change frequencies and management – *disconnect and discard*

PERIPHERAL	INTRAVENOUS CANNULA - ONGOING CARE BUNDLE
Hand Hygiene	compliance with the 5 moments of hand hygiene
nanu nyglene	<ul> <li>hands decontaminated before clean glove application</li> </ul>
Personal protective	<ul> <li>clean gloves applied immediately prior to ongoing care activities</li> </ul>
equipment	plastic apron applied if indicated
<b>Bung/line preparation</b>	<ul> <li>70% isopropyl alcohol is used and allowed to dry.</li> </ul>
Aseptic technique	<ul> <li>use an aseptic non-touch technique</li> <li>saline flushing shall be in a pulsatile (push-pause-push) motion</li> <li>Saline flush – inject at least 1-5ml of 0.9% sodium chloride into the PIVC as appropriate</li> <li>Administration of medicine as per prescription</li> <li>Saline flush – inject at least 1-5ml of 0.9% sodium chloride into the PIVC using positive pressure (clamping) technique at completion</li> </ul>
Dressing	<ul> <li>a sterile, semi-permeable, transparent dressing must remain dry and intact or is changed immediately</li> <li>if the insertion site is obscured by an opaque dressing, preventing visual inspection, this dressing must be changed</li> </ul>
Practice	<ul> <li>PIVC that are no longer clinically indicated must be removed promptly</li> <li>PIVC are left in situ in hospitalised and community care patients for the duration of therapy unless complications occur</li> <li>PIVC must be flushed with 0.9% sodium chloride to review patency each shift unless in more frequent use</li> <li>PIVC insertion sites must be revealed and inspected each shift, (daily in the community) and every time the cannula is accessed, or infusion rates are altered</li> </ul>
Documentation	<ul> <li>PIVC(s) site location, appearance (using the 0-5 visual infusion phlebitis scale), and on-going care requirements must be recorded daily in the PADP care plan, as available, or in an alternate area specified location e.g. the patient care flow chart</li> <li>any other actions, significant or exceptional findings must be documented in the appropriate clinical record</li> </ul>
Safety	<ul> <li>use needleless access systems</li> <li>use leur lock connections</li> <li>sharps container for point of care disposal</li> </ul>
Removal	<ul> <li>dressing is removed gently, use of adhesive remover if skin is fragile</li> <li>PIVC is removed slowly and gentle pressure is applied as tolerated for 2-3 mins or until bleeding stops</li> <li>site is assessed and dressing applied</li> <li>integrity of PIVC is checked before disposal in to biohazard bag</li> <li>if site appears infected, swab is taken and sent to microbiology for culture and sensitivity</li> <li>site is covered with an adhesive dressing, left in place for 24 hrs</li> <li>date, time and reason for removal is documented in the clinical notes</li> <li>a reportable event form is completed if required</li> </ul>



# Look after them properly ANTT – aseptic non-touch technique

### ANTT is based on a unique concept called:

'Key-Part and Key-Site Protection'



ANTT teaches users to **IDENTIFY** the **Key-Parts** of the equipment and **Key-Sites** of the patient that need to be **aseptic** – and then **PROTECT** them from contamination at all times

...using basic precautions such as hand cleaning and PPE, plus a combination of aseptic fields and non touch technique.





#### Peripheral & central intravenous access

ANTT preparation and administration of therapies







7



Disinfect the tray (front then back) using a large alcohol based surface wipe - creating a general 'clean' field.

Decontamination zone



place around tray.



v non-sterile Appr gloves (as preferred sterile gloves if you

**Open equipment** 

protecting key-parts

technique (ANTT).



key parts protected.



Remove Place prepared therapies and

gloves if

Patient zone



Gain clear access to the IV access device.



Apply non-sterile gloves (use sterile gloves if you cannot protect key-parts).



#### Scrub key parts

- use a large 70% alcohol wipe - scrub the bung, starting on the tip

scrub on and away from the tip, down the sides using different areas of the wipe for 15 seconds

allow time to dry.





Check cannula and insertion site presence appearance function

each shift.



**Dispose of sharps** & equipment appropriately.



Remove gloves.





Document - therapy administration in the medication chart

Document - cannula and insertion site observations daily in the PADP.

immediately.



Clean tray (front then back) with a soap/detergent wipe or warm soapy water





# Look after them properly

- Mandate ANTT education of all healthcare professionals at under and post graduate levels – DONM and CMO approval
  - assessments to include theory, verbal reasoning and practical competency assessment
- Mechanism for infection of cannula
  - System factors
  - Human factors
  - Environmental factors
  - Patient factors
- Equipment design buy closed systems, swabbable surfaces, mechanically acceptable designs



### Audit

CARE PROCESS AUDIT: Peripheral IV Cannula (PIVC) Management						DPORD RI TE UNU HALDRA
KEY CA stient bservation , Tick whe	INTERVENTIONS →	1 Dressing(s) secure, clean and appropriate Mark Y or N	2 Site inspection with phlebitis score for all PIVC(s) Mark Y if phlebitis score S1	3 PIVC(s) insitu have appropriate site selection (cannula location) Mark Y if appropriate	4 PIVC(s) inserted in Wellington or Kenepuru hospitals Mark Y or N	5 PIVC clinically indicated Mark Y or N
1 PIVC	2 PIVC					
tal number of time revention was perf						
WHEN CARE WAS G ) patients: total nun i patients: total nun	nber x 10	%	%	%	%	%
omments:						
actice focus require	ed:					
inical area and audi	tor name:				Date:	/ /

- Meaningful process and outcome measures
  - Monitor compliance, review complications, disseminate learnings



#### **CARE PROCESS AUDIT: Peripheral IV Cannula (PIVC) Management**

#### Criteria for Care process Audit

#### Dressing(s) secure, clean and appropriate

- If all PIVC dressings are intact, clean and dry and no blood visible Mark Y If all PIVC sites are visible with semi-permeable, transparent dressing allowing observation of insertion site. Mark N If one or more PIVC dressings are not intact, clean or dry If PIVC sites are not visible because insertion site is covered by a dressing that prevents site assessment i.e. the insertion site is obscured by an opaque dressing that prevents assessment. PIVC(s) site inspection using phlebitis score
- Mark Y When phlebitis score(s)  $\leq 1$
- Mark N PIVC site visible and phlebitis score >1
  - PIVC is not visible because insertion site obscured with a dressing that prevents assessment.

#### Insertion location: PIVC(s) site selection

- Mark Y If one or more PIVC are sited in the hand/arm:
  - in skin that is healthy, intact and free of bruising
  - away from areas of flexion and/or bony prominences i.e. the forearm, above or below the antecubital fossa
  - at least 5-10cm away from the radius of the wrist on the ventral surface (palm side)
  - in veins free from complication, arteriovenous shunt or fistula •
  - where there is no anatomic deformity, lymphoedema, paraesthesia or paralysis ٠
  - is not affected by breast surgery or lymph node dissection.

#### If one or more PIVC are sited in the hand/arm: Mark N

- in areas of skin inflammation, disease, bruising, oedema or breakdown, or previous IV infiltration
- ٠ in areas of flexion and/or over bony prominences - including the antecubital fossa
- within a 5-10cm radius of the wrist on the ventral surface (palm side)
- ٠ veins affected by phlebitis, sclerosis, or thrombosis, with arteriovenous shunt or fistula.
- affected by anatomic deformity, lymphoedema, paraesthesia or paralysis. ٠
- affected by breast surgery or lymph node dissection.

#### Insertion environment: PIVC(s) inserted in Wellington or Kenepuru hosptials

- Mark Y 1 or more PIVC insitu were inserted in Wellington or Kenepuru hospitals.
- Mark N 1 or more PIVC insitu were inserted in the community, an alternative hospital/healthcare environment or by ambulance services.

#### PIVC(s) clinically indicated

- PIVC is considered *clinically indicated* if it meets the following criteria:
  - Used for IV fluids and/or IV medication within 8hrs of audit
  - Used for a procedure within 8hrs of the audit
  - Insitu due to medical instability (e.g. seizures, GI bleed, cardiac monitoring)
  - Insitu for other planned used within 24hrs of audit.
- Mark N

Mark Y

PIVC only used for flushes

PIVC (s) are insitu 'just in case' and are not authorised by the medical team, with the appropriate clinical indications documented in the clinical notes.

#### PHLEBITIS SCORE

All patients with a PIVC should have the IV site checked every shift for signs of complications. The cannula site must be observed:

- When bolus injections are administered
- IV flows rates are checked or altered
- When solution containers are changed

	Phlebitis Score Card					
		• IV site appears hea	althy	0	no signs of phlebitis Observe Cannula	
1 OF:		<ul> <li>Slight pain near IV</li> <li>Slight redness near</li> </ul>		1	possible first signs Observe Cannula	
2 OF:		<ul><li>Pain at IV site</li><li>Erythema</li></ul>	Swelling	2	early stage of phlebitis Resite Cannula	
ALL OF:		<ul> <li>Pain along path of cannula</li> </ul>	<ul><li>Erythema</li><li>Induration</li></ul>	3	mid-stage of phlebitis Resite Cannula Consider Treatment	
ALL OF:		<ul> <li>Pain along path of cannula</li> <li>Erythema</li> </ul>	<ul> <li>Palpable venous cord</li> <li>Induration</li> </ul>	4	advanced stage of phlebitis or start of thrombophlebitis Resite Cannula Consider Treatment	
ALL OF:		<ul> <li>Pain along path of cannula</li> <li>Erythema</li> <li>Induration</li> </ul>	<ul> <li>Palpable venous cord</li> <li>Pyrexia</li> </ul>	5	advanced stage of thrombophlebitis Initiate Treatment Resite Cannula	





### Surveillance

- Data for PIVC infection history difficult to obtain or analyse
  - Underreporting
  - No denominator of line days
  - Lack of focus until infection poor documentation and record of observations
  - Fear of acc reporting
- Investigation tool and activity useful data
  - IV/IPC collaboration promotes understanding



## **Collaboration**

REVIEW®DAY 2	DOCTOR REVIEW	
This patient has been on	Antibiotics still indicated?	1
Since: DD/MM/YYYY ( days)	Yes No	
Date: DD/MM/YYYY Staff:	Suitable for oral switch? Yes 🔲 No 🗌	
Suitable oral option is available	Reason (if continuing IV) :	
When patient has been Afebrile >24hrs		ß
Infectious condition is suitable for oral treatment* Tolerating oral or nasogastric food or fluid		SEE NOTES
Clinical and laboratory trend towards improvement	Can IV line be removed?	SEE
Haematology & Oncology patients excluded	Yes 🗌 No 🗌	3
* Excludes bacterial endocarditis, CNS infection, cystic fibrosis and bone or joint infection - discuss with infectious diseases.	Review date	REVIEW
	Signature	2
IV to Oral Antibiotic SWITCH Criteria	CHOOSE	

uriteria





# Vascular Access Matters

- Campaign early device removal, include in related campaigns like antibiotic stewardship programmes
- Reduce cannulation
- PIVC insertion and maintenance bundles
- Everyone is responsible for prevention and control of infection

